<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.106140</article-id><article-id pub-id-type="publisher-id">ACM-35960</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20200600000_11114139.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  间质性肺疾病与肿瘤标记物及血清因子的关系研究进展
  Research Progress on the Relationship between Interstitial Lung Disease and Tumor Markers and Serum Factors
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>段</surname><given-names>兴秋</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>null</addr-line></aff><aff id="aff2"><label>1</label><addr-line>大理大学临床医学院，云南 大理</addr-line></aff><pub-date pub-type="epub"><day>29</day><month>05</month><year>2020</year></pub-date><volume>10</volume><issue>06</issue><fpage>914</fpage><lpage>919</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    近年来，间质性肺疾病引起了人们越来越多的重视，学者对其的研究也越来越多。众多学者尤其是国外学者研究发现：① 间质性肺疾病患者血清中部分肿瘤标记物，如CEA、CA19-9、SCC等会有一定程度的升高，但需警惕存在继发或者合并肿瘤的情况；② 不同原因所致的间质性肺疾病，血清肿瘤标记物升高的水平不同；③ 肿瘤标记物升高的水平可能与疾病的严重程度、治疗效果及转归有关；④ 除肿瘤标记物外，间质性肺疾病患者血清因子也有一定程度的升高，部分血清因子具有预测结局的作用。
    In recent years, interstitial lung disease has attracted more and more attention, and more and more scholars have studied it. Many scholars, especially foreign scholars, have found that: ① Some tumor markers in the serum of patients with interstitial lung disease, such as CEA, CA19-9, SCC, etc., will increase to a certain extent, but it is necessary to be alert for the presence of secondary or combined tumors Situation; ② Interstitial lung disease caused by different reasons, the level of elevated serum tumor markers is different; ③ The increased level of tumor markers may be related to the severity of the disease, treatment effect and outcome; ④ In addition to tumor markers, the serum factor of patients with interstitial lung disease also increased to a certain extent, and some serum factors have the effect of predicting the outcome. 
  
 
</p></abstract><kwd-group><kwd>间质性肺疾病，肿瘤标记物，血清因子, Interstitial Lung Disease</kwd><kwd> Tumor Marker</kwd><kwd> Serum Factor</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>间质性肺疾病与肿瘤标记物及血清因子的关系研究进展<sup> </sup></title><p>段兴秋</p><p>大理大学临床医学院，云南 大理</p><p>收稿日期：2020年5月15日；录用日期：2020年5月29日；发布日期：2020年6月5日</p><disp-formula id="hanspub.35960-formula8"><graphic xlink:href="//html.hanspub.org/file/10-1571328x5_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>近年来，间质性肺疾病引起了人们越来越多的重视，学者对其的研究也越来越多。众多学者尤其是国外学者研究发现：① 间质性肺疾病患者血清中部分肿瘤标记物，如CEA、CA19-9、SCC等会有一定程度的升高，但需警惕存在继发或者合并肿瘤的情况；② 不同原因所致的间质性肺疾病，血清肿瘤标记物升高的水平不同；③ 肿瘤标记物升高的水平可能与疾病的严重程度、治疗效果及转归有关；④ 除肿瘤标记物外，间质性肺疾病患者血清因子也有一定程度的升高，部分血清因子具有预测结局的作用。</p><p>关键词 :间质性肺疾病，肿瘤标记物，血清因子</p><disp-formula id="hanspub.35960-formula9"><graphic xlink:href="//html.hanspub.org/file/10-1571328x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/10-1571328x7_hanspub.png" /> <img src="//html.hanspub.org/file/10-1571328x8_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>间质性肺疾病(interstitial lung disease, ILD)：亦称为弥漫性实质性肺疾病(DPLD)，是一组主要累及肺间质及肺泡腔，导致肺泡–毛细血管功能单位丧失的弥漫性肺疾病。临床上表现进行性加重的呼吸困难、限制性通气功能碍伴弥散功能降低、低氧血症及影像学改变 [<xref ref-type="bibr" rid="hanspub.35960-ref1">1</xref>]。ILD病因多样，临床上分为四大类，目前最常见为结缔组织病所致，近年提出睡眠紊乱，尤其是OSA患者，可能会促进疾病进展，但缺乏客观证据 [<xref ref-type="bibr" rid="hanspub.35960-ref2">2</xref>]。</p><p>肿瘤标记物是一类在肿瘤发生或存在过程中由肿瘤细胞分泌或是由肿瘤引起机体分泌的一类血清标志物，其存在对肿瘤的诊断及病情活动、预后有重要作用，如癌胚抗原(carcinoembryonic antigen, CEA)、神经原特异性烯醇化酶(Neuron-specific enolase, NSE)、细胞角蛋白19片段抗原(Cytokeratin 19 fragment antigen 21-1, CYPRA21-1)、癌抗原19-9 (Carbohydrate antigen 19-9 CA199)等，肿瘤标记物在许多良性病变中也会有一定程度的升高，如ILD、生殖系统的良性肿瘤等，因此临床上不能单单根据肿瘤标记物的高低来判断肿瘤性及非肿瘤性疾病，结合临床及其它相关检查十分必要。</p><p>ILD不仅严重影响患者的生活质量，并且由于抗纤维化药物昂贵，给家庭及社会带来严重的经济负担，相关研究还发现，ILD是缺血性心肌病及心肌梗塞的危险因素 [<xref ref-type="bibr" rid="hanspub.35960-ref3">3</xref>]，因此人们对间质性肺疾病越来越重视，关于其与肿瘤标记物之间关系的研究越来越多，同时由于疾病存在过程中血清中许多炎症因子及免疫因子也发生变化，这些变化往往与疾病的严重程度、预后、治疗效果密切相关，因此对间质性肺疾病与血清肿瘤标记物及血清因子之间关系的研究十分具有临床价值。</p></sec><sec id="s4"><title>2. 间质性肺疾病与肿瘤标记物</title><p>一项关于IPF、COPD-ILD、CTD-ILD、肺腺癌、健康人血清中CEA、CYFRA21-1、CA19-9水平的回顾性研究中发现，参考检测方法标准范围，IPF患者血清中CEA、CA19-9阳性率明显高于其他非肺癌组，IPF组血清CYFRA21-1阳性检出率明显高于健康体检组、COPD-ILD组，而与CTD-ILD无明显差异，IPF患者血清中CEA水平总体低于肺腺癌患者。此外，该项研究将上述肿瘤标记物水平与血气、肺功能等结合分析发现，CEA水平升高者血气、FVC% pred、DLCO% pred水平均明显低于正常组 [<xref ref-type="bibr" rid="hanspub.35960-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.35960-ref5">5</xref>]，但肿瘤标记物的变化是否与疾病严重程度有关，及两者间什么样的变化关系，该项研究并未给出明确答案。另一位学者研究有基本相同的发现，与COPD患者相比，ILD患者中血清肿瘤标记物升高较明显，但与肺癌组相比，肺癌组升高更为显著，差异是否具有统计学意义，需根据肿瘤标记物的具体类别来看，而且肿瘤标记物的升高程度并不能作为肺癌与ILD的鉴别，还需结合其他检测手段 [<xref ref-type="bibr" rid="hanspub.35960-ref6">6</xref>]，Sanguinetti等 [<xref ref-type="bibr" rid="hanspub.35960-ref7">7</xref>] 却有相反结论，血清CEA在几种非肺癌的肺部疾病中并无明显统计学差异。临床上肺癌会继发间质性肺疾病，间质性肺疾病也会继发肺癌，多位学者研究发现，ILD将促进非小细胞肺癌患者术后发生不良结局，降低其生存率 [<xref ref-type="bibr" rid="hanspub.35960-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.35960-ref9">9</xref>]，这给患者带来沉重打击，当两者同时存在时，无法判断何者为先，但肿瘤标记物的变化可能会有所不同，相关研究发现CEA在单纯肺癌患者与肺癌合并间质性肺疾病者两者中阳性率有所不同，并且CEA的水平在一定程度上可能反应了肺癌分期，CEA越高者肺癌分期越晚 [<xref ref-type="bibr" rid="hanspub.35960-ref10">10</xref>]。ILD病因众多，不同病因引起肺纤维化的机制有所不同，从而在疾病过程中引起机体的变化有所差异，有研究者对不同病因所致的间质性肺疾病中部分血清肿瘤标记物进行统计学比较，发现不同病因所致的ILD患者中，部分血清肿瘤标记物存在差异，并有统计学意义(P &lt; 0.05) [<xref ref-type="bibr" rid="hanspub.35960-ref11">11</xref>]，由结缔组织病继发ILD的患者中，肿瘤标记物及炎症因子，如CEA、IL-6、CRP等比单纯结缔组织病者更容易升高 [<xref ref-type="bibr" rid="hanspub.35960-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.35960-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.35960-ref14">14</xref>]。</p><p>鳞状细胞癌抗原(Squamous cell carcinoma antigen, SCC)为一种丝氨酸蛋白酶抑制剂，机体各部位发生鳞状细胞癌时其表达增高，但并不像甲胎蛋白对于肝癌那样特异，相关研究发现IPF患者中SCC表达显著升高，同时发现SCC可能在IPF病程中发挥促纤维化的作用，由此导致病情向着不可逆的方向发展 [<xref ref-type="bibr" rid="hanspub.35960-ref15">15</xref>]。在关于肺气肿与肺间质纤维化患者血清细胞因子及肿瘤标记物的研究中，两者血清中SCC却无统计学差异，血管内皮生长因子(VEGF)，转化生长因子-β1 (TGF-β1)和CYFRA21-1等可能在肺纤维化的发病机制中起作用 [<xref ref-type="bibr" rid="hanspub.35960-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.35960-ref17">17</xref>]，近年研究表明甲泼尼龙与乙酰半胱氨酸对ILD治疗上无明显获益，但两者联合治疗可以显著降低上述部分血清因子，并能改善肺功能及血气指标 [<xref ref-type="bibr" rid="hanspub.35960-ref18">18</xref>]。</p><p>Mukae [<xref ref-type="bibr" rid="hanspub.35960-ref19">19</xref>] 等学者对两例间质性肺炎患者的观察发现，两位患者在治疗有效时血清中CA19-9水平呈现下降趋势，而当病情恶化时明显升高，可见该肿瘤标志物的水平与病情波动有关。另一例研究发现职业粉尘所致的间质性肺炎患者中CA19-9明显升高，机制不明 [<xref ref-type="bibr" rid="hanspub.35960-ref20">20</xref>]。一名65岁的IIP患者血清中CA19-9明显升高，该患者合并胰腺癌，被考虑为CA19-9升高的原因，但后来肺组织活检抗CA19-9抗体的免疫组织化学染色为阳性，病变区域扁平和长方化生上皮细胞覆盖，抗CA19-9抗体染色也为阳性，那么是否可以据此考虑CA19-9由病变区域上皮细胞分泌 [<xref ref-type="bibr" rid="hanspub.35960-ref21">21</xref>] ？</p></sec><sec id="s5"><title>3. 间质性肺疾病与血清因子水平</title><p>ILD始动因素目前还未明确，可能由于各种遗传、免疫、环境等因素相互作用于肺泡上皮细胞及血管内皮细胞，激发体内炎症细胞，释放炎症因子，导致肺组织反复损伤，刺激成纤维细胞及胶原纤维，最终导致纤维化 [<xref ref-type="bibr" rid="hanspub.35960-ref22">22</xref>]。因此ILD患者血清中可能出现各种炎症细胞及细胞因子，这些炎症细胞及因子的水平视病情的严重程度、亚类的不同、疾病的不同阶段而有所不同。</p><p>机体后天形成的免疫中，发挥免疫应答的主要有T淋巴细胞(主要包括CD4<sup>+</sup> T细胞、CD8<sup>+</sup> T细胞)及B淋巴细胞(主要包括B1细胞、B2细胞)，两者相辅相成，通过一系列机制抵御外界有害物质入侵，Th1细胞、Th2细胞是CD4<sup>+</sup> T细胞的两个亚型，(近年来又发现了Th22，但其具体作用及其与CTD、ILD的关系尚不明确 [<xref ref-type="bibr" rid="hanspub.35960-ref23">23</xref>])，它们分泌的细胞因子称为Th1/Th2细胞因子，早在十多年前，我国学者就研究发现，在ILD患者中，Th1、Th2细胞因子是导致肺纤维化的主要原因，尤其是Th2细胞因子介导的的体液免疫发挥着主要作用，而Th1细胞因子中的IFN-γ具有调节成纤维细胞增值及胶原沉积的作用而具有抗纤维化的作用 [<xref ref-type="bibr" rid="hanspub.35960-ref24">24</xref>]，Ishikawa Yuichi [<xref ref-type="bibr" rid="hanspub.35960-ref14">14</xref>] 等国外学者在皮肌炎患者继发快速进展危及生命的ILD患者的肺及肺门淋巴结中发现有大量IFN-γ阳性组织细胞浸润。相关研究对比健康人、CTD患者、CTD-ILD患者血清中IL-9，IL-4和IFN-γ的水平，发现IL-9，IL-4在三者中的水平依次升高，血清中IL-9的水平与IFN-γ水平呈负相关，由此可见IL-9在CTD及CTD-ILD中发挥重要作用 [<xref ref-type="bibr" rid="hanspub.35960-ref25">25</xref>]。高铁蛋白血症常常与PM/DM患者出现快速进展ILD(RP-ILD)同时存在，IL-6，IL-8和IL-10是导致PM/DM高铁蛋白血症的关键因素，可以考虑对几种细胞因子的调节，为RP-ILD防治提供策略 [<xref ref-type="bibr" rid="hanspub.35960-ref26">26</xref>]。原发性干燥综合症患者是否继发ILD，其血清中IL-34水平并无显著差异，但IL-34可能参与疾病发展过程中B淋巴细胞的活化及抗体的产生 [<xref ref-type="bibr" rid="hanspub.35960-ref27">27</xref>]。在RA患者中，发生RA-ILD可能与血清中IL-4有密切关系，RA与RA-ILD中IL-13和IL-5的水平却没有明显差异 [<xref ref-type="bibr" rid="hanspub.35960-ref28">28</xref>]，涎液化糖链抗原-6 (KL-6)，主要表达于损伤的肺泡II型上皮，在结缔组织病肺部改变中发挥着重要作用，且KL-6水平与疾病结局密切相关，KL-6水平高者预后不良 [<xref ref-type="bibr" rid="hanspub.35960-ref29">29</xref>] [<xref ref-type="bibr" rid="hanspub.35960-ref30">30</xref>]。</p><p>趋化因子是由多种细胞分泌的对不同细胞具有趋化作用的细胞因子，具有趋化、调节免疫细胞、调节血细胞、并在机体发生肿瘤、感染等过程中发挥重要作用，几乎所有趋化因子均含半胱氨酸残基所形成的分子内二硫键，根据靠近氨基端的半胱氨酸残基的个数以及排列顺序，将趋化因子分为四个亚家族：C亚家族、CC亚家族、CXC亚家族、CX3C亚家族 [<xref ref-type="bibr" rid="hanspub.35960-ref31">31</xref>]，Sfriso等 [<xref ref-type="bibr" rid="hanspub.35960-ref32">32</xref>] 研究发现未发展为ILD的系统性硬化患者BALF样本中CXCL11浓度明显升高，通过BALF中CXCL11水平的测定可预测患者肺功能水平。CXCL13可能是预测IPF患者预后的生物学标志物 [<xref ref-type="bibr" rid="hanspub.35960-ref33">33</xref>]。在探讨CCL18在结缔组织病相关性间质性肺病中的表达时发现：RA-ILD，DM-ILD和pSS-ILD组BALF中CCL18水平均明显高于对照组(无ILD的患者)，CCL18的水平与淋巴细胞百分比呈正相关，且CCL18可以作为CTD-ILD严重程度和预后的指标 [<xref ref-type="bibr" rid="hanspub.35960-ref34">34</xref>]，Elhai等 [<xref ref-type="bibr" rid="hanspub.35960-ref35">35</xref>] 学者也得出了相同结论。Scc-ILD患者中CCL2水平可作为疾病进展及预后的生物标志物，并且可据此研究疾病新的治疗靶点 [<xref ref-type="bibr" rid="hanspub.35960-ref36">36</xref>]。</p><p>一项关于AE-CTD-ILD与AE-IPF患者的研究中，发现两者急性加重的发生率相同，但CTD-ILD的死亡率明显降低，WBC计数及PO<sub>2</sub>/FiO<sub>2</sub>对患者生存率产生重要作用 [<xref ref-type="bibr" rid="hanspub.35960-ref37">37</xref>]。Kawamura等 [<xref ref-type="bibr" rid="hanspub.35960-ref38">38</xref>] 学者研究发现外周单核细胞计数ILD患者发生急性加重的独立重要危险因素，计数增加预示着患者预后不良。相关研究表明，不同分类的间质性肺疾病其支气管肺泡灌洗液(BALF)中各种细胞所占的比例各有不同，细胞计数有利于ILD的诊断 [<xref ref-type="bibr" rid="hanspub.35960-ref39">39</xref>]，作者研究的样本较小，对结果的准确性可能有一定的影响。一项回顾性研究发现：ILD患者碳氧血红蛋白(CO-Hb)水平明显高于健康人，急性加重时尤为明显，且与血清炎症指数呈现正相关关系(r = 0.57)，与动脉血氧分压负相关(r = −0.56) [<xref ref-type="bibr" rid="hanspub.35960-ref40">40</xref>]。pSS-ILD与单纯pSS患者相比，其口干，眼球干燥和麻木更为常见，血清C反应蛋白(CRP)和免疫球蛋白G (IgG)水平更高 [<xref ref-type="bibr" rid="hanspub.35960-ref41">41</xref>]。</p></sec><sec id="s6"><title>4. 结论</title><p>间质性肺疾病患者血清中肿瘤标记物及血清因子水平会发生一定的变化，这些变化可能与疾病的严重程度、转归、治疗效果密切相关，那么我们据此可以思考对上述肿瘤标记物及血清因子的检测，达到指导治疗，预测疾病复发及结局、减轻疾病负担等作用。当然更多有益于患者的发现，需要大家进行更多的研究。</p></sec><sec id="s7"><title>文章引用</title><p>段兴秋. 间质性肺疾病与肿瘤标记物及血清因子的关系研究进展Research Progress on the Relationship between Interstitial Lung Disease and Tumor Markers and Serum Factors[J]. 临床医学进展, 2020, 10(06): 914-919. https://doi.org/10.12677/ACM.2020.106140</p></sec><sec id="s8"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.35960-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">万学红, 卢雪峰, 主编. 诊断学[M]. 第8版. 北京: 北京人民卫生出版社, 2013.</mixed-citation></ref><ref id="hanspub.35960-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Myall Katherine J,West Alex,Kent Brian D. (2019) Sleep and Interstitial Lung Disease. Current Opinion in Pulmonary Medicine, 25, 623-628. &lt;br&gt;https://doi.org/10.1097/MCP.0000000000000620</mixed-citation></ref><ref id="hanspub.35960-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Clarson, L.E., Bajpai, R., Whittle, R., et al. (2020) Interstitial Lung Disease Is a Risk Factor for Ischaemic Heart Disease and Myocardial Infarction. Heart, 2020, 1-7. &lt;br&gt;https://doi.org/10.1136/heartjnl-2019-315511</mixed-citation></ref><ref id="hanspub.35960-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">杜瑞娇. 肿瘤标记物与肺间质纤维化的相关性分析及临床观察[D]: [硕士学位论文]. 大连: 大连医科大学, 2016.</mixed-citation></ref><ref id="hanspub.35960-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">张书印, 丁选胜, 方芸. 细胞角蛋白19片断在间质性肺病诊断中的临床意义[J]. 药学与临床研究, 2017, 25(4): 318-320.</mixed-citation></ref><ref id="hanspub.35960-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">林蕊艳, 张新, 李晓辉, 胥振扬. 间质性肺疾病血清肿瘤标记物升高的临床意义[J]. 中国临床药理学杂志, 2011, 27(8): 623-625.</mixed-citation></ref><ref id="hanspub.35960-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Sanguinetti, C.M., Riccioni, G., Marchesani, F., et al. (1995) Bronchoalveolar Lavage Fluid Level of Carcinoembryonic Antigen in the Diagnosis of Peripheral Lung Cancer. Monaldi Archives for Chest Disease, 50, 177-182.</mixed-citation></ref><ref id="hanspub.35960-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Tao, H., Onoda, H., Okabe, K., et al. (2018) The Impact of Coexisting Lung Diseases on Outcomes in Patients with Pathological Stage I Non-Small-Cell Lung Cancer. Interactive Cardiovascular and Thoracic Surgery, 26, 1009-1015.  
&lt;br&gt;https://doi.org/10.1093/icvts/ivx441</mixed-citation></ref><ref id="hanspub.35960-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Sekihara, K., Aokage, K., Oki, T., et al. (2018) Long-Term Survival after Complete Resection of Non-Small-Cell Lung Cancer in Patients with Interstitial Lung Disease. Interactive Cardiovascular and Thoracic Surgery, 26, 638-643.  
&lt;br&gt;https://doi.org/10.1093/icvts/ivx400</mixed-citation></ref><ref id="hanspub.35960-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">王玉超, 杨晓红, 邬超. 特发性肺纤维化合并肺癌患者血液肿瘤标志物CEA、CA199、CA125、CA153检测分析[J]. 山东医药, 2013, 53(29): 78-79.</mixed-citation></ref><ref id="hanspub.35960-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">李文飞. 肿瘤标志物与不同类型间质性肺病关系探讨[D]: [硕士学位论文]. 天津: 天津医科大学, 2019.</mixed-citation></ref><ref id="hanspub.35960-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">熊晓静. CTD-ILD患者血清学指标的临床意义[D]: [硕士学位论文]. 乌鲁木齐: 新疆医科大学, 2019.</mixed-citation></ref><ref id="hanspub.35960-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">朱红林, 杜倩, 谌威霖, 左晓霞, 李全贞, 刘思佳. 系统性硬化症血清细胞因子表达谱变化及调控机制[J]. 北京大学学报(医学版), 2019, 51(4): 716-722.</mixed-citation></ref><ref id="hanspub.35960-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Ishikawa, Y., Iwata, S., Hanami, K., et al. (2018) Relevance of Interferon-Gamma in Pathogenesis of Life-Threatening Rapidly Progressive Interstitial Lung Disease in Patients with Dermatomyositis. Arthritis Research &amp; Therapy, 20, 240.  
&lt;br&gt;https://doi.org/10.1186/s13075-018-1737-2</mixed-citation></ref><ref id="hanspub.35960-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Calabrese, F., Lunardi, F. and Giacometti, C. (2008) Over Expression of Squamous Cell Carcinoma Antigen in Idiopathic Pulmonary Fibrosis: Clinico Pathological Correlations. Thorax, 63, 795-802.  
&lt;br&gt;https://doi.org/10.1136/thx.2007.088583</mixed-citation></ref><ref id="hanspub.35960-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Xu, L., Bian, W., Gu, X.H., et al. (2017) Differing Expression of Cytokines and Tumor Markers in Combined Pulmonary Fibrosis and Emphysema Compared to Emphysema and Pulmonary Fibrosis. COPD, 14, 245-250.  
&lt;br&gt;https://doi.org/10.1080/15412555.2017.1278753</mixed-citation></ref><ref id="hanspub.35960-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">张立, 王强. 多发性肌炎(PM)/皮肌炎(DM)相关的肺间质病变发(ILD)病机制的研究进展[J]. 复旦学报(医学版), 2015, 42(2): 267-272.</mixed-citation></ref><ref id="hanspub.35960-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">曹路, 高宝安, 官莉, 陈世雄. 乙酰半胱氨酸+甲基强的松龙对IIP患者血气指标、肺功能及血清炎症因子的影响[J]. 中华肺部疾病杂志(电子版), 2019, 12(6): 738-742.</mixed-citation></ref><ref id="hanspub.35960-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Mukae, H., Sakito, O., Oda, H., Senju, R., et al. (1991) Two Cases of Interstitial Pneumonitis with Marked Increase of Tumor-Associated Carbohydrate Antigens in Serum. Nihon Kyōbu Shikkan Gakkai Zasshi, 29, 611-617.</mixed-citation></ref><ref id="hanspub.35960-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Seike, M., Usuki, J., Uematsu, K., et al. (1995) Giant Cell Interstitial Pneumonia in a Metal Grinder with an Abnormally High Level of Serum CA19-9. Nihon Kyōbu Shikkan Gakkai Zasshi, 33, 894-899.</mixed-citation></ref><ref id="hanspub.35960-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Sugiyama, M., Ito, K., Iyonaga, K., et al. (1997) Idiopathic Interstitial Pneumonia Associated with a High Level of CA19-9 in Serum and with CA19-9 in Lung Tissue. Nihon Kyōbu Shikkan Gakkai Zasshi, 35, 561-565.</mixed-citation></ref><ref id="hanspub.35960-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">牟晓燕, 林殿杰, 辛洪涛. 肺间质纤维化的分子生物学发病机制及治疗新进展[J]. 国际呼吸杂志, 2006(12): 928-931.</mixed-citation></ref><ref id="hanspub.35960-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Truchetet, M.E., Brembilla, N.C., Montanari, E., et al. (2011) Increased Frequency of Circulating Th22 in Addition to Th17 and Th2 Lymphocytes in Systemic Sclerosis: Association with Interstitial Lung Disease. Arthritis Research &amp; Therapy, 13, R166. &lt;br&gt;https://doi.org/10.1186/ar3486</mixed-citation></ref><ref id="hanspub.35960-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">赵素霞, 王燕. 细胞因子与间质性肺疾病的发病机制[J]. 国际呼吸杂志, 2006(8): 625-628.</mixed-citation></ref><ref id="hanspub.35960-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Jiang, S., Wang, Z., Ouyang, H., et al. (2016) Aberrant Expression of Cytokine Interleukin 9 along with Interleukin 4 and Interferon γ in Connective Tissue Disease-Associated Interstitial Lung Disease: Association with Severity of Pulmonary Fibrosis. Archives of Medical Science, 12, 101-106. &lt;br&gt;https://doi.org/10.5114/aoms.2015.47877</mixed-citation></ref><ref id="hanspub.35960-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Kawasumi, H., Gono, T., Kawaguchi, Y., et al. (2014) IL-6, IL-8, and IL-10 Are Associated with Hyperferritinemia in Rapidly Progressive Interstitial Lung Disease with Polymyositis/Dermatomyositis. BioMed Research International, 2014, Article ID: 815245. &lt;br&gt;https://doi.org/10.1155/2014/815245</mixed-citation></ref><ref id="hanspub.35960-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Liu, Y., Zhang, B., Lei, Y., et al. (2020) Serum Levels of Interleukin-34 and Clinical Correlation in Patients with Primary Sjögren’s Syndrome. International Journal of Rheumatic Diseases, 23, 374-380.  
&lt;br&gt;https://doi.org/10.1111/1756-185X.13773</mixed-citation></ref><ref id="hanspub.35960-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Shen, H., Xia, L. and Lu, J. (2013) Interleukin-4 in Rheumatoid Arthritis Patients with Interstitial Lung Disease: A Pilot Study. The Indian Journal of Medical Research, 138, 919-921.</mixed-citation></ref><ref id="hanspub.35960-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">孙迪, 程哲, 蒋天赐, 李鹏飞, 贾留群, 王婷婷, 郑曹沛, 李妍, 堕梦洁. 肺功能和KL-6在抗合成酶综合征相关间质性肺疾病与特发性肺纤维化中的特点及临床意义[J]. 中华医学杂志, 2020(10): 748-752.</mixed-citation></ref><ref id="hanspub.35960-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Kim, H.C., Choi, K.H., Jacob, J., et al. (2020) Prognostic Role of Blood KL-6 in Rheumatoid Arthritis-Associated Interstitial Lung Disease. PLoS One, 15, e0229997. &lt;br&gt;https://doi.org/10.1371/journal.pone.0229997</mixed-citation></ref><ref id="hanspub.35960-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">曹雪涛. 医学免疫学-8版[M]. 北京: 北京人民卫生出版社, 2013.</mixed-citation></ref><ref id="hanspub.35960-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Sfriso, P., Cozzi, F., Oliviero, F., et al. (2012) CXCL11 in Bronchoalveolar Lavage Fluid and Pulmonary Function Decline in Systemic Sclerosis. Clinical and Experimental Rheumatology, 30, S71-S75.</mixed-citation></ref><ref id="hanspub.35960-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Guo, L., Yang, Y., Liu, F., et al. (2019) Clinical Research on Prognostic Evaluation of Subjects with IPF by Peripheral Blood Biomarkers, Quantitative Imaging Characteristics and Pulmonary Function Parameters. Archivos de Bronconeumología, in Press. &lt;br&gt;https://doi.org/10.1016/j.arbres.2019.08.020</mixed-citation></ref><ref id="hanspub.35960-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">贺新伟, 骆琼珍, 尚颖, 高占成. CCL18在结缔组织病相关间质性肺疾病BALF中的表达及临床意义[J]. 中华医学杂志, 2019, 99(38): 2976-2981.</mixed-citation></ref><ref id="hanspub.35960-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Elhai, M., Avouac, J. and Allanore, Y. (2020) Circulating Lung Biomarkers in Idiopathic Lung Fibrosis and Interstitial Lung Diseases Associated with Connective Tissue Diseases: Where Do We Stand? Seminars in Arthritis and Rheumatism, in Press. &lt;br&gt;https://doi.org/10.1016/j.semarthrit.2020.01.006</mixed-citation></ref><ref id="hanspub.35960-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Wu, M., Baron, M., Pedroza, C., et al. (2017) CCL2 in the Circulation Predicts Long-Term Progression of Interstitial Lung Disease in Patients with Early Systemic Sclerosis: Data from Two Independent Cohorts. Arthritis &amp; Rheumatology, 69, 1871-1878. &lt;br&gt;https://doi.org/10.1002/art.40171</mixed-citation></ref><ref id="hanspub.35960-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Cao, M., Sheng, J., Qiu, X., et al. (2019) Acute Exacerbations of Fibrosing Interstitial Lung Disease Associated with Connective Tissue Diseases: A Population-Based Study. BMC Pulmonary Medicine, 19, Article No.: 215.  
&lt;br&gt;https://doi.org/10.1186/s12890-019-0960-1</mixed-citation></ref><ref id="hanspub.35960-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">Kawamura, K., Ichikado, K., Anan, K., et al. (2020) Monocyte Count and the Risk for Acute Exacerbation of Fibrosing Interstitial Lung Disease: A Retrospective Cohort Study. Chronic Respiratory Disease, 17, 1-8.  
&lt;br&gt;https://doi.org/10.1177/1479973120909840</mixed-citation></ref><ref id="hanspub.35960-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">Efared, B., Ebang-Atsame, G., Rabiou, S., et al. (2017) The Diagnostic Value of the Bronchoalveolar Lavage in Interstitial Lung Diseases. Journal of Negative Results in BioMedicine, 16, Article No.: 4.  
&lt;br&gt;https://doi.org/10.1186/s12952-017-0069-0</mixed-citation></ref><ref id="hanspub.35960-ref40"><label>40</label><mixed-citation publication-type="other" xlink:type="simple">Hara, Y., Shinkai, M., Kanoh, S., et al. (2017) Arterial Carboxyhemoglobin Measurement Is Useful for Evaluating Pulmonary Inflammation in Subjects with Interstitial Lung Disease. Internal Medicine, 56, 621-626.  
&lt;br&gt;https://doi.org/10.2169/internalmedicine.56.7418</mixed-citation></ref><ref id="hanspub.35960-ref41"><label>41</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, T., Yuan, F., Xu, L., et al. (2020) Characteristics of Patients with Primary Sjögren’s Syndrome Associated Interstitial Lung Disease and Relevant Features of Disease Progression. Clinical Rheumatology, 39, 1561-1568.  
&lt;br&gt;https://doi.org/10.1007/s10067-019-04906-6</mixed-citation></ref></ref-list></back></article>